

Curriculum Vitae Prof. Dr Iris Löw-Friedrich

Academic degree: Dr. med. University of Frankfurt/Main

Occupation: Chief Medical Officer and Executive Vice President Development and Medical Practices at UCB S.A., Brussels, Belgium

Clinical professor for internal medicine at University of Frankfurt/Main, Medical School (since 2000)

Place of residence: Ratingen, Germany

Personal data

Year of birth: 1960

Nationality: Deutsch

Member of the Supervisory Board of Evotec SE

First appointed on 17 June 2014

Last elected at the Annual General Meeting on 17 June 2014 until the Annual General Meeting, which will decide on the approval of the members of the Supervisory Board for fiscal year 2018

Education

1985 University of Frankfurt/Main
Conferral of a doctorate (Dr. med.)

1979 – 1985 University of Frankfurt/Main
Study of medicine

Professional career

Since 2008 UCB S.A.
Chief Medical Officer and Executive Vice President Development and Medical Practices

2001 – 2009 Schwarz Pharma AG
Member of the Executive Board, Global responsibility for research and development

2000 – 2001 BASF Pharma

	Vice President Global Projects
Since 2000	University of Frankfurt/Main Clinical professor for internal medicine
1992 – 2000	Hoechst AG Various positions, most recent position of Vice President Clinical Development

Appointments to other statutory supervisory boards and comparable national and international supervisory bodies of commercial enterprises

Fresenius SE & Co. KGaA (Member of the Supervisory)

TransCelerate BioPharma Inc (Member of the Supervisory)

Other significant activities besides the Supervisory Board mandate

n/a

Relevant knowledge, skills and experience

Prof. Dr Iris Löw-Friedrich (born in 1960, German citizen) was appointed Member of the Supervisory Board on 17 June 2014 for a term of five years. Her current term will expire at the end of the AGM held in the year 2019. Since March 2008, Prof. Dr Iris Löw-Friedrich has been serving as Chief Medical Officer and Executive Vice President Development and Medical Practices of UCB S.A., Brussels (Belgium). From 2001 to 2009, Prof. Dr Löw-Friedrich was a member of the Executive Board of Schwarz Pharma AG, Monheim am Rhein, with global responsibility for research and development. From 2000 to 2001, she served as Vice President Global Projects at BASF Pharma, Ludwigshafen. From 1992 to 2000, Prof. Dr Löw-Friedrich held various positions in the area of drug development at Hoechst AG, Frankfurt am Main, lastly as Vice President Clinical Development at Hoechst Marion Roussel/Aventis, Bridgewater, NJ, USA. Since April 2014, she has been Member of the Supervisory Board at TransCelerate BioPharma Inc (Chairman of the Supervisory Board from September 2015 until September 2017). Since May 2016, Prof. Dr Löw-Friedrich has been serving as Member of the Supervisory Board of Fresenius SE & Co. KGaA.

Prof. Dr Löw-Friedrich began her career in 1985 as a physician in the field of internal medicine at the University of Frankfurt/Main, Medical School, where she has also been a clinical professor for internal medicine since 2000. She studied medicine at the University of Frankfurt/Main, receiving her doctorate from this university in 1985.

Due to her clinical expertise, Prof. Dr Löw-Friedrich ideally complements the future Supervisory Board of Evotec SE and expands its range of competences.

Personal or business relationships in accordance with section 5.4.1 paragraphs 6 to 8 of the German Corporate Governance Code

In the opinion of the Supervisory Board, Prof. Dr Iris Löw-Friedrich and Evotec SE, its affiliates, the bodies of Evotec SE or a significant shareholder in Evotec SE, have no personal or business relationships that an objective judging shareholder would consider authoritative for their voting decision. Shareholders who directly or indirectly hold more than 10% of the Company's voting shares are considered as significant shareholders.